of an increased transplant-related mortality. [4][5] [6] [7] [8] [9] [10] The curative potential of allo-BMT is due to both the graft-versusleukemia (GVL) effect and the antitumoral activity of the Attempts to improve the efficacy of pretransplant conditioning regimens have been published, the potential preparative regimen used before transplantation. [11] [12] [13] Various attempts to improve the efficacy of antileukemic treatof a better antileukemic effect being impaired by more frequent and severe toxicities. The efficacy of an intensiments have already been published. [14] [15] [16] [17] [18] [19] [20] [21] In most studies the potential of a better antileukemic effect was impaired by fied regimen, TAM (TBI, high-dose cytosine arabinoside and melphalan), is evaluated by analyzing long-term folthe more frequent and severe toxicities when compared with the standard total body irradiation (TBI) and cyclopholow-up of a homogenous group of 42 high-risk ALL patients allografted in first CR. Age at time of BMT was sphamide regimen. Results have previously been reported of an intensified preparative regimen, TAM including frac-25.9 ± 10.4 years (3-41). Twenty-two patients had more than three adverse prognostic factors. Ten patients had tionated TBI, high-dose cytosine arabinoside (HD Ara-C) and high-dose melphalan (HDM), before autologous or a Ph chromosome. Probability of overall survival was 45 ± 9%, and for all surviving patients median followallogeneic BMT in a heterogeneous group of ALL patients. [22] [23][24] [25] [26] The efficacy of this TAM pretransplant regiup time was 66 months. Event-free survival was 40 ± 8% at 7 years after transplantation and the men is now re-evaluated by analyzing long-term follow-up of a new homogenous group of 42 high-risk ALL patients expected relapse rate reached 31%. Twenty-two deaths occurred, six after a relapse but 16 appeared to be allografted in first CR. directly due to the BMT procedure. None of the pretransplant characteristics significantly affected outcome after BMT. TAM appeared to be an efficient antileuPatients and methods kemic therapy for conditioning high-risk ALL patients before allogeneic transplantation, but was still very Patients toxic. The use of TAM in adult ALL patients in first CR is not recommended and the real role of intensified Forty-two ALL patients, recruited from 10 French BMT units between 15 June 1987 and 15 November 1991 were conditioning regimens remains to be demonstrated. Keywords: acute lymphoblastic leukemia; bone marrow included in this retrospective study (16 females and 26 males). Only two patients had already been included in our transplantation; total body irradiation; cytosine arabinoside; melphalan previous reports. Age at time of BMT ranged from 3 to 41 years (mean 25.9 ± 10.4 years). Five patients were less than 15 years and 19 more than 30 years of age. Diagnosis of ALL was according to the FAB classification. 27 Phenotype Relapse remains the main cause of death and failure of was analyzed by indirect immunofluorescence using flow treatment in high-risk acute lymphoblastic leukemia (ALL) cytometry and a panel of monoclonal antibodies to deterpatients.
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of an increased transplant-related mortality. [4] [5] [6] [7] [8] [9] [10] The curative potential of allo-BMT is due to both the graft-versusleukemia (GVL) effect and the antitumoral activity of the Attempts to improve the efficacy of pretransplant conditioning regimens have been published, the potential preparative regimen used before transplantation. [11] [12] [13] Various attempts to improve the efficacy of antileukemic treatof a better antileukemic effect being impaired by more frequent and severe toxicities. The efficacy of an intensiments have already been published. [14] [15] [16] [17] [18] [19] [20] [21] In most studies the potential of a better antileukemic effect was impaired by fied regimen, TAM (TBI, high-dose cytosine arabinoside and melphalan), is evaluated by analyzing long-term folthe more frequent and severe toxicities when compared with the standard total body irradiation (TBI) and cyclopholow-up of a homogenous group of 42 high-risk ALL patients allografted in first CR. Age at time of BMT was sphamide regimen. Results have previously been reported of an intensified preparative regimen, TAM including frac-25.9 ± 10.4 years (3-41). Twenty-two patients had more than three adverse prognostic factors. Ten patients had tionated TBI, high-dose cytosine arabinoside (HD Ara-C) and high-dose melphalan (HDM), before autologous or a Ph chromosome. Probability of overall survival was 45 ± 9%, and for all surviving patients median followallogeneic BMT in a heterogeneous group of ALL patients. [22] [23] [24] [25] [26] The efficacy of this TAM pretransplant regiup time was 66 months. Event-free survival was 40 ± 8% at 7 years after transplantation and the men is now re-evaluated by analyzing long-term follow-up of a new homogenous group of 42 high-risk ALL patients expected relapse rate reached 31%. Twenty-two deaths occurred, six after a relapse but 16 appeared to be allografted in first CR. directly due to the BMT procedure. None of the pretransplant characteristics significantly affected outcome after BMT. TAM appeared to be an efficient antileu- in six patients (Table 1 ). All patients were transplanted within 11 ± 8 (4-54) weeks after achieving of CR; 36
patients were grafted before the 12th week post-CR and one patient beyond the 1st year post-remission induction. ent induction regimens were used. All contained anthracyclines, vincristine and corticosteroids during the first 4
BMT procedure weeks. Various chemotherapeutic agents were then Ten Gy single dose TBI was used in 14 cases. All patients employed as post-induction treatment until BMT was completed the preparative regimen and were evaluated for planned.
non-hematological toxicities. Three young adults (15 Ͻ age Ͻ 30 years) and five children received full doses of Ara-BMT procedure C, 25 patients received 12 g/m 2 and nine patients only 3-8 g/m 2 of Ara-C because of previous CNS or early skin The original TAM 24 pretransplant regimen was initially toxicities. Ten Gy single dose TBI was used in 14 cases. planned for children and consisted of either 10 Gy single Severe (OMS grade у3) gastro-intestinal and oral mucodose or 12 Gy fractionated TBI (six fractions in 3 days), sitis were noted in more than 75% of the cases. All patients HD Ara-C 3 g/m 2 over 3 h every 12 h for eight doses (24 but one engrafted and surviving patients achieved sustained g/m 2 total dose) and HDM 140 mg/m 2 over a 30 to 60 hematopoiesis. Sixteen non-leukemic deaths were min infusion. In view of our previous results in terms of observed: 72% of the 22 deaths and 38% of overall poputoxicity, [22] [23] [24] it was decided to reduce by half the dose of lation (42 patients). Eight were observed in the 23 patients Ara-C (12 g/m 2 total dose) in non-pediatric patients (age Ͻ30 years (34%) and eight in the 19 older patients (42%). Ͼ15 years). All donors were fully HLA-matched siblings.
Acute GVHD (grade у2) was diagnosed in 12 (23%) Graft-versus-host disease (GVHD) prophylaxis consisted of patients and chronic GVHD in four, extensive in three cyclosporin A and methotrexate in 39 cases, cyclosporin A cases. GVHD was the direct or contributing cause of death and corticosteroids in two cases and T cell depletion of the in 11 cases, nine with grade III-IV aGVHD and two with graft in one case. GVHD was evaluated using Glucksberg's chronic extensive GVHD. There was no significant differscoring system. 30 This BMT procedure was submitted for ence in GVHD rate or severity according to age. The other the approval of a local Ethical Committee in each particicauses of death were systemic aspergillosis in one case, pating center.
CMV disease in two cases, capillary-leak syndrome in one case and septic shock in one.
Statistical analysis
Survival duration was calculated from the date of BMT Survival until date of death or last known date alive. When calculating event-free survival (EFS), both relapses and deaths in Median post-transplant survival time was 28 (0-92) months and for all surviving patients median follow-up time was CR were counted as events. Survival curves were estimated EFS rates varying from 25% to greater than 60%. Inclusion criteria and pretransplant characteristics differ widely from one study to another allowing no real comparison between different reports. Nevertheless, results of allogeneic BMT in terms of overall and disease-free survival (DFS) are clearly superior to those of chemotherapy, with or without autologous BMT 4-7 for patients in second or subsequent CR.
The results of allo-BMT in first CR remain more controversial. Most series report a DFS of 40-50%, associated with a high toxic death rate ranging fom 25 to 35%.
4-10,33-39
An analysis of the International Bone Marrow Transplantation Registry showed that allogeneic transplantation was advantage was offset by a toxic death rate reaching 38% in the BMT arm vs 4% for chemotherapy alone. 6 In a recent study Sebban et al 9 found no statistical difference but a 66 months (46-92). At the time of analysis, 20 patients clear trend in favor of allo-BMT in a randomized trial were alive in continuous CR. The probabilities of overall including 257 patients. 9 When only high-risk patients were survival and EFS were respectively of 45 ± 9% and considered, there was a significant advantage for allo-BMT 39.8 ± 8% at 92 months post-BMT (Figures 1 and 2) . Seven in first CR (39 ± 8% and 14 ± 5% DFS at 2 years for allorelapses occurred, with all but two relapsed patients dying BMT and control arm, respectively). In another French a few months after relapse. The two patients entering a study, Attal et al 4 describe a randomized trial of 135 second CR had relapsed 4 and 5 years post-BMT; one patients receiving either allo-or auto-BMT for ALL in remained in continuous remission at 36+ months after CR1. In this study the probability of DFS was significantly relapse and the second died from leukemia 21 months after higher in the allo-BMT compared with the auto-BMT arm the diagnosis of relapse. Probability of relapse reached 31%
(71 vs 30%, respectively). 4 at 5 years post-BMT (Figure 2 ). Event-free survival Allogeneic BMT is more often offered to patients at high appeared better for Ph+ patients because of a lower toxic risk for treatment failure with standard chemotherapy regideath rate (30%) as compared to Ph− patients (48%), while mens. 7, 10, 28, 29, [33] [34] [35] [36] [37] [38] [39] High-risk leukemia was defined using the percentages of relapses were 13% and 30% respectcriteria previously described by Hoelzer et al 29 in a large ively, but no significant difference was observed regarding series of patients and then confirmed by Sebban et al 5, 9 survival and relapse. None of the other pretransplant in their own series: Ph chromosome, leukocytosis characteristics, including age at time of BMT, alone or in у30 × 10 9 /l, age у30 years, a delay Ͼ8 weeks to obtain combination, significantly affected the outcome or the CR and non-T cell immunophenotype. The presence of relapse rate after BMT (Table 2) .
CNS involvement as an adverse prognostic factor was retained in this study and in fact all of our CNS+ patients died post-BMT (five toxic deaths) questioning the role of Discussion HD-Ara-C in patients with previous CNS damage. Patients were considered at risk if at least one of these adverse progExtensive data concerning allo-BMT in ALL are now availnostic factors was present; this was the case for all of our able. [4] [5] [6] [7] [8] [9] [10] [13] [14] [15] [19] [20] [21] [22] [23] [24] [25] [26] 28, 29, [33] [34] [35] [36] [37] [38] [39] Studies usually report estimated patients. The risk of relapse or death was not statistically different between patients with only one adverse factor and those with Ͼ1 factor, but groups were too small to draw definite conclusions; it was observed that six of the seven relapses occurred in patients with at least four adverse prognostic factors. Different strategies to improve antileukemic effects of the pretransplant regimens have been tested, using additional chemotherapy or higher doses of TBI.
1, [16] [17] [18] [19] [20] [21] The efficacy of HD-Ara-C and HDM have been demonstrated in the treatment of refractory or relapsing acute leukemias. [16] [17] [18] [19] [20] [21] There is currently no clear evidence that intensified preparative regimens have a better antileukemic effect than the standard cyclophosphamide + TBI, while in fact they exhibit greater toxicities. The feasibility and toxicity of the TAM regimen before allogeneic and autologous viously reported. [22] [23] [24] [25] [26] This regimen would appear to be 42 ALL patients allografted in CR1. At 5 years, EFS = 40% and relapse rate = 31%. efficient in terms of antileukemic efficacy, but exhibits a The TAM regimen appears to be an efficient antileukemic treatment for conditioning highfound a significant advantage for the TAM regimen among a group of 42 ALL children allografted in CR2. Recent risk ALL patients before allogeneic transplantation but toxicity remains the major problem and this regimen is not data from EBMT, IBMTR and others 12, 14, 15, 34 mention a DFS of 54-61% after allo-BMT in adults with high-risk recommended for adult patients over 30 years of age. Since the 1990s, progress in supportive care has probably reduced ALL, respectively. These recent results are similar to ours and probably mean that intensifying the conditioning regitransplant mortality by at least 10% and our results must be re-evaluated in the light of these data, but the real value men is not the way to improve survival after BMT.
Our present work confirms the antileukemic efficacy of in intensifying preparative regimens has not been clearly demonstrated. One part of the answer to the question: 'Is TAM on a homogenous group of young adult ALL patients at high risk of relapse (69% of DFS). The relapse rate in more better?' lies with the GVL effect and its potential for modulation rather than in enhancing conditioning regimens. this group of high-risk patients is low, seven of 42 patients (16%). Thirteen percent of Ph− and 30% of Ph+ patients relapsed but data detailed in Table 2 must be interpreted with caution because of the small sample size. It was noted Acknowledgements that younger patients (Ͻ30 years) did better than older ones in terms of relapse-free survival, but the groups were too This work was in part supported by a grant from the 'Ligue dépar-small to show a significant difference between groups. Sevtementale du Doubs contre le cancer'. enteen (40%) non-relapsing patients, with more than 5 years post-BMT follow-up might be considered to be cured. The toxic death rate, in contrast, is very high (38%) despite References a reduction in HD-Ara-C (24 g/m 2 ) for three quarters of patients, and this fact explains the discrepancy between our played a role as a triggering agent in the GVHD process.
3603-3612.
However, it may be hypothesized that the high incidence of 
